The Recall Desk

State

New York product recalls

73,892 recalls have nationwide distribution and so reach New York. 12,964 additional recalls listed New York specifically in their distribution scope.

What the numbers show

Total
12,964
Critical
1,508
Severe
3,707
Most recent
2026-11-11

Of the 12,964 recalls naming New York we have scored against our rubric, 1,508 (12%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 3,707 (29%) are Severe.

These figures cover only the 12,964 recalls whose distribution notice names New York specifically. The 73,892 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

64476–64500 of 86856

  • CriticalFDA (Devices)·Z-1462-2015·2015-04-29

    Laax Recalls TIGERPAW System II Implantable Occlusion Fasteners

    Laax, Inc. is recalling TIGERPAW System II implantable fasteners due to reports of tissue tearing and bleeding during use.

    Product
    TIGERPAW System II, Part number C-TP-1509 (9 connector) The TigerPaw System II is an implantable occlusion Fastener to be placed on the Ostium of the Left Atrial Appendage (LAA).
    Category
    Medical Device
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-887-2015·2015-04-29

    Attix Pharmaceuticals Recalls Satraplatin Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Satraplatin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Satraplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-711-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydralazine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydralazine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Hydralazine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-756-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levocetirizine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levocetirizine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Levocetirizine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-511-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amikacin Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Amikacin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amikacin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-834-2015·2015-04-29

    Attix Pharmaceuticals Recalls Paroxetine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Paroxetine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Paroxetine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-867-2015·2015-04-29

    Progesterone API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling progesterone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Progesterone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-611-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dantrolene Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dantrolene Sodium API lots distributed between January 2012 and February 2015 due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dantrolene Sodium (Light Yellow) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-500-2015·2015-04-29

    Attix Pharmaceuticals Recalls Acetylsalicyclic Acid Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling acetylsalicyclic acid active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Acetylsalicyclic acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-0969-2015·2015-04-29

    Hospira Recalls 0.9% Sodium Chloride Injection Due to Human Hair Particulate

    Hospira is recalling 0.9% Sodium Chloride Injection, USP, 250 mL, because a human hair was found sealed in the bag at the additive port area.

    Product
    0.9% Sodium Chloride Injection, USP, 250 mL, Rx Only, Hospira Inc., Lake Forest, IL, 60045, USA, NDC 0409-7983-02
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-694-2015·2015-04-29

    Attix Pharmaceuticals Recalls Furazolidine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Furazolidine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Furazolidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Devices)·Z-1498-2015·2015-04-29

    Wright Medical Recalls Crosscheck Plating System Due to Specification Defects

    Wright Medical Technology is recalling 100 units of Crosscheck Plating Systems because dimensional specifications are out of tolerance, posing a risk of intraoperative malfunction.

    Product
    CROSSCHECK(R) Plating system, Utility Plate, 6-Hole, REF CCP-UTN6. Orthopedic use.
    Category
    Medical Device
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-874-2015·2015-04-29

    Attix Pharmaceuticals Recalls Quinine Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Quinine Sulfate Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Quinine Sulfate Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-706-2015·2015-04-29

    Attix Pharmaceuticals Recalls Histamine Phosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Histamine Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Histamine Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-589-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cisatracurium Besylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cisatracurium Besylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cisatracurium Besylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-665-2015·2015-04-29

    Attix Pharmaceuticals Recalls Etomidate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Etomidate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Etomidate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-586-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cimetidine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cimetidine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cimetidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-653-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Estradiol (Micronized) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Estradiol (Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-683-2015·2015-04-29

    Fluorexon API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Fluorexon active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Fluorexon active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-953-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vidarbine Monophosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vidarbine Monophosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Vidarbine Monophosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-930-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tiopronin Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tiopronin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tiopronin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-906-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sulfanilamide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sulfanilamide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Sulfanilamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-718-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxocobalamin Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxocobalamin Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydroxocobalamin Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-556-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcitriol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling calcitriol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Calcitriol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-606-2015·2015-04-29

    Cyclophosphamide Monohydrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Cyclophosphamide Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Cyclophosphamide Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide